CardiologyOnline.net

Cardiology Xagena

The new drug LCZ696 is a treatment for chronic heart failure. LCZ696 is better than conventional drugs at reducing cardiac death and hospitalization due to heart failure. Now, researchers from Kuma ...


Findings from more than 135,000 individuals from 18 low, middle and high-income countries in the Prospective Urban-Rural Epidemiology ( PURE ) study have shown that high carbohydrate intake is linked ...


Dark chocolate enriched with extra virgin olive oil is associated with an improved cardiovascular risk profile, according to research presented at ESC Congress. According to Rossella Di Stefano at ...


Treatment of myocardial infarction patients depends on their history of cancer, according to research published in European Heart Journal: Acute Cardiovascular Care. The study in more than 35 000 my ...


New data from Evolocumab ( Repatha ) cardiovascular outcomes trial ( FOURIER ) were presented at the 2017 National Lipid Association Scientific Sessions, which showed that Evolocumab consistently and ...


Physicians have long touted the short- and long-term health benefits of breastfeeding, but a research has shown it also may reduce a woman’s risk of having a myocardial infarction or stroke later in l ...


Results from the global phase III CANTOS study investigating the efficacy, safety and tolerability of Canakinumab ( ACZ885 ) in combination with standard of care in people with a prior myocardial inf ...


A new study by researchers at the Intermountain Medical Center Heart Institute in Salt Lake City found that using long-term Aspirin ( Acetylsalicylic acid ) therapy to prevent strokes among patients w ...


As the Zika virus continues to spread globally, new evidence has emerged about the virus's potentially detrimental effects on the heart. The study included adult patients with no prior history of c ...


Evolocumab ( Repatha ), a PCSK9 inhibitor, has shown to dramatically lower levels of low-density lipoprotein ( LDL), and also the risk of cardiovascular events in patients with existing heart or vascu ...


Amid growing uncertainty about the safety of Digoxin, a commonly used heart drug, a study led by Duke Clinical Research Institute found that people with atrial fibrillation should avoid taking the dru ...


Findings from a real-world data analysis of the U.S. Medicare database comparing the risk of stroke or systemic embolism and rate of major bleeding among patients with non-valvular atrial fibrillation ...


Although studies have examined the association between dietary Magnesium intake and health outcome, the results are inconclusive. Researchers have conducted a dose–response meta-analysis of prospect ...


Although there are many different antiarrhythmic drugs approved for rhythm management of atrial fibrillation, little comparative effectiveness data exist to guide drug selection. Researchers follow ...


Catheter ablation of ventricular tachycardia in patients with nonischemic dilated cardiomyopathy can be challenging because of the complexity of underlying substrates. Researchers sought to determin ...